Fulgent Genetics, Inc. (FLGT) Earnings Call Analysis

NASDAQ · Healthcare · Diagnostics & Research

11/25

Growth 2 Margin 1 Expansion 5 Platform 1 Financial 2

latest quarter score

Earnings Reports

11
Fulgent Genetics (FLGT) Q2 2026: $19M Revenue Hit from Billing Transition Drives Guidance Reset
July 31, 2026
10
Fulgent Genetics (FLGT) Q1 2026: Customer Shift Drives $6M Revenue Decline, Pathology Expansion Offsets Concentration Risk
May 01, 2026
9
Fulgent Genetics (FLGT) Q4 2025: $59M Customer Loss Offset by 53% AP Expansion and AI Leverage
February 27, 2026
22
Fulgent Genetics (FLGT) Q3 2025: Lab Services Margins Rise to 44.3% on AI and Digital Pathology Gains
November 07, 2025
18
Fulgent Genetics (FLGT) Q2 2025: Core Revenue Jumps 16% as Managed Care and Genomics Expansion Accelerate
August 01, 2025
23
Fulgent Genetics (FLGT) Q1 2025: Biopharma Services Jump 51% as Core Diagnostics Expand Market Share
July 06, 2025
Fulgent Genetics (FLGT) Q4 2024: 14% Core Revenue Growth Highlights Laboratory Services Momentum Amid Therapeutics Pipeline Advancement
February 28, 2025

Browse all companies